A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
-
Moreira AL
Department of Pathology, New York University Langone Health, New York, New York. Electronic address: andre.moreira@nyumc.org.
-
Ocampo PSS
Department of Pathology, New York University Langone Health, New York, New York.
-
Xia Y
Department of Biostatistics, New York University Langone Health, New York, New York.
-
Zhong H
Department of Biostatistics, New York University Langone Health, New York, New York.
-
Russell PA
Department of Pathology, St. Vincent's Hospital, Victoria, Australia.
-
Minami Y
Department of Pathology, Ibarakihigashi National Hospital, Tokai, Japan.
-
Cooper WA
Department of Pathology, Royal Prince Alfred Hospital, Camperdown, Australia.
-
Yoshida A
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
-
Bubendorf L
Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Switzerland.
-
Papotti M
Department of Oncology, University of Turin, Turin, Italy.
-
Pelosi G
Department of Pathology, University of Milan, Milan Italy; IRCCS MultiMedica, Milan Italy.
-
Lopez-Rios F
Pathology-Laboratorio de Dianas Terapeuticas, HM Hospitales, Madrid, Spain.
-
Kunitoki K
Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
-
Ferrari-Light D
Department of Surgery, New York University Langone Health, New York, New York.
-
Sholl LM
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
-
Beasley MB
Department of Pathology, Icahn School of Medicine, Mount Sinai Health System, New York, New York.
-
Borczuk A
Department of Pathology, Weill Cornell Medicine, New York, New York.
-
Botling J
Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University Hospital, Uppsala, Sweden.
-
Brambilla E
Department of Anatomic Pathology and Cytology, Université Grenoble Alpes, Grenoble, France.
-
Chen G
Department fo Pathology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
-
Chou TY
Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan.
-
Chung JH
Department of Pathology, Seoul National University Bundang Hospital, Seoul, South Korea.
-
Dacic S
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
-
Jain D
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
-
Hirsch FR
Center for Thoracic Oncology, The Tisch Cancer Institute, New York, New York.
-
Hwang D
Department of Laboratory Medicine & Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
-
Lantuejoul S
Department fo Pathology, Centre Léon Bérard Unicancer, Lyon, France.
-
Lin D
Department of Pathology, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
-
Longshore JW
Carolinas Pathology Group, Atrium Health, Charlotte, North Carolina.
-
Motoi N
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
-
Noguchi M
Department of Pathology, University of Tsukuba, Tsukuba, Japan.
-
Poleri C
Office of Pathology Consultants, Buenos Aires, Argentina.
-
Rekhtman N
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
-
Tsao MS
University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
-
Thunnissen E
Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
-
Travis WD
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
-
Yatabe Y
Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
-
Roden AC
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
-
Daigneault JB
International Association for the Study of Lung Cancer, Aurora, Colorado.
-
Wistuba II
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
-
Kerr KM
Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.
-
Pass H
Department of Surgery, New York University Langone Health, New York, New York.
-
Nicholson AG
Department of Pathology, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Kingdom.
-
Mino-Kenudson M
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Show more…
Published in:
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. - 2020
English
INTRODUCTION
A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a set of histologic criteria associated with prognosis aimed at establishing a grading system for invasive pulmonary adenocarcinoma.
METHODS
A multi-institutional study involving multiple cohorts of invasive pulmonary adenocarcinomas was conducted. A cohort of 284 stage I pulmonary adenocarcinomas was used as a training set to identify histologic features associated with patient outcomes (recurrence-free survival [RFS] and overall survival [OS]). Receiver operating characteristic curve analysis was used to select the best model, which was validated (n = 212) and tested (n = 300, including stage I-III) in independent cohorts. Reproducibility of the model was assessed using kappa statistics.
RESULTS
The best model (area under the receiver operating characteristic curve [AUC] = 0.749 for RFS and 0.787 for OS) was composed of a combination of predominant plus high-grade histologic pattern with a cutoff of 20% for the latter. The model consists of the following: grade 1, lepidic predominant tumor; grade 2, acinar or papillary predominant tumor, both with no or less than 20% of high-grade patterns; and grade 3, any tumor with 20% or more of high-grade patterns (solid, micropapillary, or complex gland). Similar results were seen in the validation (AUC = 0.732 for RFS and 0.787 for OS) and test cohorts (AUC = 0.690 for RFS and 0.743 for OS), confirming the predictive value of the model. Interobserver reproducibility revealed good agreement (k = 0.617).
CONCLUSIONS
A grading system based on the predominant and high-grade patterns is practical and prognostic for invasive pulmonary adenocarcinoma.
-
Language
-
-
Open access status
-
bronze
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/299403
Statistics
Document views: 38
File downloads: